glp-1 out of pocket NEW FOR 2026: Medicare Bridge Program Access to eligible weight-loss medications for approximately $50/month* *Eligibility and physician approval required. Starting July 1, 2026, Medicare will launch a new temporary program called For all our Medicare folks

The effect is modest compared to pharmaceutical intervention but measurable and relevant for people managing prediabetes and blood sugar swings

1 Although 3 medicationsacamprosate, disulfiram, and naltrexoneare approved by the Food and Drug Administration (FDA) for the treatment of AUD, and although both acamprosate and naltrexone are recommended in American Psychiatric Association guidelines based on extensive safety and efficacy data, 6 less than 2% of individuals with AUD are prescribed these medications

Even if your insurance plan won't help you out, this makes GLP-1 access more accessible and affordable to many people across the nation

References 1 Abdel-MegeedR

One example from each of the common diabetes classes is listen in Table 4 since other medications in the same class typically have similar costs

Second cardiovascular safety trial to demonstrate that a GLP-1R agonist reduces MACE and microvascular (including renal) events in patients with T2DM and high cardiovascular risk